Sweden's Alligator Bioscience AB said Janssen Biotech Inc. has terminated its 2015 licensure of the Swedish company's CD40-directed antibody, ADC-1013, following a strategic portfolio decision to prioritize other assets. Read More
LONDON – Wellington Partners has reported the final close of its fifth fund at €210 million (US$234 million), well above the initial target range of €120 million to €150 million. Read More
DUBLIN – Alizé Pharma 3 SAS closed a €67 million (US$75.7 million) series A round to progress a pair of preclinical assets in development for rare endocrine and metabolic disorders. Read More
Achieving statistically significant improvement over placebo with JAK inhibitor ATI-501 didn't satisfy Aclaris Therapeutics Inc.'s shareholders as the stock (NASDAQ:ACRS) dramatically dropped 26.4% on Wednesday. Read More
U.S. Health and Human Services (HHS) Secretary Alex Azar announced Wednesday that HHS and the FDA are finally opening a door Congress provided decades ago to allow prescription drugs to be imported from Canada. Read More
HONG KONG – Chengdu-based Hinova Pharmaceuticals Inc., of China's Sichuan province, closed a series B financing that added $40 million to the company's pocket. Read More
LONDON – Clinical artificial intelligence (AI) specialist Sensyne Health plc agreed to a two-year collaboration with Bayer AG, in which it will apply its algorithms to analyze 3 million medical records, with the aim of identifying disease subtypes that support patient stratification in phase III trials in cardiovascular disease. Read More
Medicenna Therapeutics Corp., of Toronto, selected long-acting IL-2 MDNA-19 (formerly, MDNA-109-LA1) as its second immuno-oncology clinical candidate. Read More
Ironwood Pharmaceuticals Inc., of Cambridge, Mass., reported Linzess (linaclotide) U.S. net sales, as provided by its U.S. collaboration partner, Allergan plc, of Dublin, were $196 million in the second quarter. Read More
The FDA issued a draft guidance Wednesday on general clinical pharmacology considerations for neonatal drug studies as an adjunct to a 2014 draft guidance on pediatric studies. Read More
Vaccinex Inc., of Rochester, N.Y., said it entered a stock purchase agreement with a syndicate of new and existing investors for a private placement of 3.38 million shares at $4.08 each for aggregate gross proceeds of approximately $13.8 million. Read More
